Weight-Loss Drug Pipeline Swells as Competitors Challenge Market Leaders

A wave of pharmaceutical companies are advancing new weight-loss drugs through their development pipelines, intensifying competition in a lucrative market currently dominated by Novo Nordisk and Eli Lilly. With analysts forecasting the sector could generate $100 billion in annual sales within the next decade, established players and new entrants are racing to develop more effective and convenient treatments.

Market Leaders Defend Turf

Incumbents Novo Nordisk and Eli Lilly are not standing still, pushing forward with next-generation therapies to maintain their market lead. Eli Lilly reported that its experimental combination drug, EloraTZP, outperformed its blockbuster Zepbound in a mid-stage trial, with patients on the highest dose losing an average of 23.3% of their body weight over 48 weeks. The company also announced that another candidate, retatrutide, helped patients lose more than 28% of their weight over 18 months.

Novo Nordisk is developing several new treatments, including a next-generation injection called amycretin, which targets both GLP-1 and amylin hormones. In a mid-stage study, amycretin demonstrated a weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes. The company is also pursuing approval for CagriSema, though late-stage trial data showed a 22.7% weight reduction, which was below the company's internal expectations of 25%.

Challengers Enter the Fray

Several major pharmaceutical firms are aggressively moving to capture a share of the market, often through strategic acquisitions and licensing deals. These companies are developing drugs with different mechanisms or dosing schedules.

Ad

• Pfizer: Is developing a once-monthly injection, PF-3944, which led to up to 12.3% weight loss at 28 weeks in a study. The company is targeting its first approval in the obesity market for 2028.
• Amgen: Its experimental drug MariTide helped overweight patients shed up to 20% of their body weight in a year-long mid-stage trial. The company is now conducting six late-stage trials for the drug across obesity and related conditions.
• Roche: Entered the space through its $2.7 billion acquisition of Carmot Therapeutics. Its lead candidate, enicepatide, helped patients lose an average of 15.5% of their body weight in a mid-stage trial.
• Merck and AstraZeneca: Have both signed licensing deals worth billions for experimental drugs from Chinese biotechs to establish their presence in the market.

The Race for Oral Treatments

A key area of competition is the development of oral medications, which offer greater convenience than the current weekly injections. Eli Lilly has already secured approval in the U.S. and UK for its oral pill Foundayo (orforglipron) for weight management.

Other biotechs are also reporting promising results for their oral candidates. Structure Therapeutics announced its once-daily pill, aleniglipron, helped patients lose up to 16.3% of their body weight after 44 weeks in a mid-stage trial. Similarly, Viking Therapeutics is planning a late-stage study for its oral drug after earlier trials showed significant weight loss, signaling a broader industry shift toward more patient-friendly alternatives.